Medicines labeled for the same conditions
Alternatives to revumenib
37 other medicines are given the same way (oral) and in the same FDA class as revumenib or labeled mainly for the same use (leukemia, lymphoma and myeloma); 1 is in its class, menin inhibitors: ziftomenib; the others include 11 kinase inhibitors, 3 alkylating drugs and 3 nucleoside metabolic inhibitors (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as revumenib?
The first 24 of the 37, the same class first. Leukemia, lymphoma and myeloma lists all 98 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Revumenibmenin inhibitor | this medicine | none listed | n/a | Yes | No current entry |
| Ziftomenibmenin inhibitor · same class | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | No current entry |
| Lenalidomidethalidomide analog | Leukemia, lymphoma and myeloma | 18 labelers | n/a | Yes | No current entry |
| Dasatinibkinase inhibitor | Leukemia, lymphoma and myeloma | 14 labelers | $26.46 per tablet 100 mg tablet | No | No current entry |
| Pomalidomidethalidomide analog | Leukemia, lymphoma and myeloma | 11 labelers | n/a | Yes | No current entry |
| Imatinibkinase inhibitor | Leukemia, lymphoma and myeloma | 20 labelers | $0.624 per tablet 100 mg tablet | No | No current entry |
| Arsenic trioxide | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | A presentation being discontinued |
| Nilotinibkinase inhibitor | Leukemia, lymphoma and myeloma | 6 labelers | n/a | Yes | No current entry |
| Hydroxyureaantimetabolite | Leukemia, lymphoma and myeloma | 10 labelers | $0.184 per capsule 500 mg capsule | No | No current entry |
| Cyclophosphamidealkylating drug | Leukemia, lymphoma and myeloma | 4 labelers | $1.67 per capsule 50 mg capsule | No | No current entry |
| Bosutinibkinase inhibitor | Leukemia, lymphoma and myeloma | 3 labelers | n/a | No | No current entry |
| Bexaroteneretinoid | Leukemia, lymphoma and myeloma | 7 labelers | n/a | Yes | No current entry |
| Mercaptopurinenucleoside metabolic inhibitor | Leukemia, lymphoma and myeloma | 2 labelers | $1.07 per tablet 50 mg tablet | No | No current entry |
| Ibrutinibkinase inhibitor | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Selinexornuclear export inhibitor | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Ponatinibkinase inhibitor | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | No current entry |
| Sonrotoclax | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Thalidomide | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | No current entry |
| Acalabrutinibkinase inhibitor | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Asciminib | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Ixazomibproteasome inhibitor | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Venetoclaxbcl-2 inhibitor | Leukemia, lymphoma and myeloma | none listed | n/a | No | No current entry |
| Azacitidinenucleoside metabolic inhibitor | Leukemia, lymphoma and myeloma | none listed | n/a | No | In shortage |
| Duvelisib | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | No current entry |
| Enasidenibisocitrate dehydrogenase 2 inhibitor | Leukemia, lymphoma and myeloma | none listed | n/a | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Revumenib: the full record
- label, generics, price, shortages, recalls